Wanchuan Ding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Wanchuan Ding has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Chenhui Bai
Department of Mechanical Engineering National University of Singapore Singapore Singapore
1 shared publication- Haoyuan Han
Joint Institute of Nanjing Drum Tower Hospital for Life and Health, College of Life Science, Nanjing Normal University, Nanjing 210023, China
1 shared publication - Jingjing Gan
Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Medical School, Nanjing University, Nanjing, 210008, China
1 shared publication - Juan Chen
Department of Endocrinology, The Affiliated Huai’an No.1 People’s Hospital of Nanjing Medical University, China
1 shared publication - Qiuyue Jiang
Joint Institute of Nanjing Drum Tower Hospital for Life and Health, College of Life Science, Nanjing Normal University, Nanjing 210023, China
1 shared publication - Quan Zhang
Joint Institute of Nanjing Drum Tower Hospital for Life and Health, College of Life Science, Nanjing Normal University, Nanjing 210023, China
1 shared publication
Latest Publications
- Open Access
- 12 November 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (11) , 1470
PreS1-Derived Peptide-Engineered Cell Membrane-Coated Nanoparticles Enhance Liver-Directed Curcumin Delivery in Acute Liver Injury
Background: Liver injury remains a major clinical challenge, and the therapeutic performance of many candidate drugs is limited by poor bioavailability and insufficient tissue selectivity. Methods: This study proposes a biomimetic delivery strategy based on genetically engineered cell membrane camouflage. Briefly, curcumin-loaded PLGA nanoparticles were co-ultrasonicated with genetically modified 293T cell membranes displaying a hepatocyte-binding peptide that originates from the preS1 region of the hepatitis B virus large surface protein, allowing the membrane-coated particles to self-assemble into a core–shell structure designated HBVP-MPNs, thereby achieving active hepatocyte-targeted delivery of curcumin. The resulting HBVP-MPNs were designed to engage sodium taurocholate cotransporting polypeptide (NTCP) and improve liver-directed delivery. Results: HBVP-MPNs exhibited a mean particle diameter of approximately 197.9 nm, a core–shell morphology, high curcumin encapsulation efficiency, and slower cumulative curcumin release over 24 h than uncoated PNs (35.1% versus 51.6%). They showed approximately threefold higher cell-associated fluorescence in HepG2-NTCP cells and approximately 50% lower fluorescence in RAW264.7 macrophages than PNs in vitro. Following intravenous administration in mice, HBVP-MPNs displayed prolonged blood-associated fluorescence and increased liver accumulation. Upon therapeutic evaluation in a CCl₄-triggered murine model of acute hepatic injury, HBVP-MPNs elicited markedly lower circulating ALT and AST activities and conferred superior protection against histopathological abnormalities in liver tissue relative to free curcumin and non-targeted control formulations. Cytotoxicity, hemolysis, hematological, serum biochemical, and histological assessments indicated favorable tolerability within the present experimental settings. Conclusions: Collectively, these data warrant further investigation of preS1 peptide-engineered cell membrane-coated nanoparticles as a biomimetic platform for liver-directed curcumin delivery in acute liver injury.
- 12 November 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (11) , 1470
Open AccessPreS1-Derived Peptide-Engineered Cell Membrane-Coated Nanoparticles Enhance Liver-Directed Curcumin Delivery in Acute Liver Injury
Background: Liver injury remains a major clinical challenge, and the therapeutic performance of many candidate drugs is limited by poor bioavailability and insufficient tissue selectivity. Methods: This study proposes a biomimetic delivery strategy based on genetically engineered cell membrane camouflage. Briefly, curcumin-loaded PLGA nanoparticles were co-ultrasonicated with genetically modified 293T cell membranes displaying a hepatocyte-binding peptide that originates from the preS1 region of the hepatitis B virus large surface protein, allowing the membrane-coated particles to self-assemble into a core–shell structure designated HBVP-MPNs, thereby achieving active hepatocyte-targeted delivery of curcumin. The resulting HBVP-MPNs were designed to engage sodium taurocholate cotransporting polypeptide (NTCP) and improve liver-directed delivery. Results: HBVP-MPNs exhibited a mean particle diameter of approximately 197.9 nm, a core–shell morphology, high curcumin encapsulation efficiency, and slower cumulative curcumin release over 24 h than uncoated PNs (35.1% versus 51.6%). They showed approximately threefold higher cell-associated fluorescence in HepG2-NTCP cells and approximately 50% lower fluorescence in RAW264.7 macrophages than PNs in vitro. Following intravenous administration in mice, HBVP-MPNs displayed prolonged blood-associated fluorescence and increased liver accumulation. Upon therapeutic evaluation in a CCl₄-triggered murine model of acute hepatic injury, HBVP-MPNs elicited markedly lower circulating ALT and AST activities and conferred superior protection against histopathological abnormalities in liver tissue relative to free curcumin and non-targeted control formulations. Cytotoxicity, hemolysis, hematological, serum biochemical, and histological assessments indicated favorable tolerability within the present experimental settings. Conclusions: Collectively, these data warrant further investigation of preS1 peptide-engineered cell membrane-coated nanoparticles as a biomimetic platform for liver-directed curcumin delivery in acute liver injury.
- Open Access
- 21 May 2026
- Published by Wiley in Smart Medicine
- Vol. 5 (3) , e70035
Freeze‐Derived Microporous Biomaterials for Tissue Engineering Applications
Tissue engineering holds immense promise to revolutionize regenerative medicine by enabling the fabrication of functional, patient‐specific tissues and organs for clinical translation, yet it continues to face persistent challenges in designing scaffolds that simultaneously recapitulate native tissue architecture, support cell viability, and enable efficient mass transport. Traditional fabrication has moved the field forward, yet routinely falls short of producing hierarchical, anisotropic, biomimetic structures under gentle conditions. Ice‐templating (or freeze‐casting), which is based on freeze‐induced microphase separation, reframes the problem as crystal‐growth engineering. This review summarizes current fabrication strategies and their underlying mechanism of ice‐templating technology from physical and chemical perspectives. We then highlight recent advances in ice‐templating for tissue engineering application fields such as 3D cell culture, wound healing, bone regeneration, nerve repair, and liver support, emphasizing the relationship between microstructure and biomedical functional performance. Finally, we discuss the key challenges in translating ice‐templated biomaterials from laboratory research to clinical practice and outline future directions to fully harness this versatile biomedical strategy.
- 21 May 2026
- Published by Wiley in Smart Medicine
- Vol. 5 (3) , e70035
Open AccessFreeze‐Derived Microporous Biomaterials for Tissue Engineering Applications
Tissue engineering holds immense promise to revolutionize regenerative medicine by enabling the fabrication of functional, patient‐specific tissues and organs for clinical translation, yet it continues to face persistent challenges in designing scaffolds that simultaneously recapitulate native tissue architecture, support cell viability, and enable efficient mass transport. Traditional fabrication has moved the field forward, yet routinely falls short of producing hierarchical, anisotropic, biomimetic structures under gentle conditions. Ice‐templating (or freeze‐casting), which is based on freeze‐induced microphase separation, reframes the problem as crystal‐growth engineering. This review summarizes current fabrication strategies and their underlying mechanism of ice‐templating technology from physical and chemical perspectives. We then highlight recent advances in ice‐templating for tissue engineering application fields such as 3D cell culture, wound healing, bone regeneration, nerve repair, and liver support, emphasizing the relationship between microstructure and biomedical functional performance. Finally, we discuss the key challenges in translating ice‐templated biomaterials from laboratory research to clinical practice and outline future directions to fully harness this versatile biomedical strategy.